-
Mashup Score: 8
Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 10FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs - 16 day(s) ago
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10FDA Approves 177Lu-Dotatate in Patients 12 and Up for GEP-NETs - 16 day(s) ago
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9FDA Calls for Boxed Warnings for CAR T-Cell Immunotherapies - 20 day(s) ago
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
An investigational new drug application for SynKIR-310’s phase 1 trial targeting relapsed/refractory B-cell non-Hodgkin lymphomas was submitted to the FDA.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17FDA Approves Trastuzumab Deruxtecan in HER2+ Solid Tumors - 24 day(s) ago
Fam-trastuzumab deruxtecan-nxki received accelerated approval from the FDA for adult patients with unresectable or metastatic HER2-positive solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5The Targeted Pulse: New Approvals, Including Expanded Approvals, GEJ Treatment Debates, and More - 24 day(s) ago
The FDA approves T-DXd for HER2+ tumors; SynKIR-310 trials begin, and experts debate FLOT vs. CROSS in GEJ cancer in this week’s recap article.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 45 FDA Approvals for Solid Tumors in Early 2024 - 1 month(s) ago
Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 11FDA Approves Trastuzumab Deruxtecan in HER2+ Solid Tumors - 1 month(s) ago
Fam-trastuzumab deruxtecan-nxki received accelerated approval from the FDA for adult patients with unresectable or metastatic HER2-positive solid tumors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
The #FDA approval of Enhertu for patients with HER2-positive solid tumors is an “unprecedented approval,” Dr. Sarah Sammons (@drsarahsam) of @DanaFarber @dfci_breastonc told CURE®. Read more about this treatment option: https://t.co/6B7KWzkKUt